---
document_datetime: 2023-09-21 19:15:24
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/refacto-af-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: refacto-af-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 2.0248579
conversion_datetime: 2025-12-23 20:55:16.916049
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## PROCEDURAL STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 01 October 2003, please refer to module 8B

- The MAH submitted to the EMEA on 12 July 1999 application for a Type I variation, a minor change of the manufacturing process of the active substance. Pursuant to Article 4  of  Commission  Regulation  (EC)  No  542/95  of  10  March  1995,  as  amended.  The procedure started on 30 July 1999. A positive opinion was adopted by the CPMP 20 October 1999. (EMEA/H/C/232/I/01)
- The MAH submitted on 21 September 1999 a notification to  the  EMEA  in  order  to introduce  changes  to  the  Package  Leaflet  not  connected  to  the  Summary  of  Product Characteristics,  pursuant  Article  10(3)  of  Council  Directive  No.  92/27/EEC  of  31 March 1992. The procedure started on 21 September 1999. The notification was signed by the Head of Human Medicines Evaluation Unit on 18 October 1999 and forwarded to the European  Commission  which  adopted  a  decision on 31 January 2000. (EMEA/H/C/232/N/02)
- The  MAH  submitted  to  the  EMEA  on  30  September  1999  application  for  a  Type  I variation,  replacement  of  bovine-derived  excipient  with  a  comparable  vegetablederived excipient, pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995. The procedure started on 4 October 1999. A positive notification was signed  by  the  Head  of  Human  Unit  at  the  EMEA  on  18  October  1999.  and  the European Commission which adopted a decision on 21 October 1999. (EMEA/H/C/232/I/03)
- The  MAH submitted to  the  EMEA  on  11  January  2000  an  application  for  a  Type  I variation,  a  change  of  specification  of  active  substance,  pursuant  to  Article  4  of Commission  Regulation  (EC)  No  542/95  of  10  March  1995,  as  amended.  The procedure started on 18 January 2000. A positive notification was signed by the Head ofby  the  Head  of  the  Biologicals  and  Biotechnology  sector  in  the  Unit  for  the Evaluation  of  Medicines  for  Human  Use  at  the  EMEA  16  February  2000  and  the European Commission which adopted a decision on 1 March 2000. (EMEA/H/C/232/I/04)
- The  MAH  submitted  on  26  January  2000  a  notification  to  the  EMEA  in  order  to introduce  changes  to  the  Package  Leaflet  not  connected  to  the  Summary  of  Product Characteristics,  pursuant  Article  10(3)  of  Council  Directive  No.  92/27/EEC  of  31 March 1992. The procedure started on 2 February 2000. The notification was signed by Head  of  the  Biologicals  and  Biotechnology  sector  in  the  Unit  for  the  Evaluation  of Medicines for Human Use at the EMEA on 17 February 2000 and forwarded to the European Commission which adopted a decision on 6 April 2000. (EMEA/H/C/232/N/05)
- The  MAH submitted  to  the  EMEA  on  June  2000  application  for  a  Type  I  variation change  following  modifications  to  the  manufacturing  authorisation  in  order  to  apply Wyeth Laboratories, UK as the manufacturing responsible for the batch release and to replace  the  current  one,  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No 542/95  of  10  March  1995,  as  amended.  The  procedure  started  on  14  June  2000.  A positive notification was  signed  by  the Head  of  Head  of  the Biologicals  and Biotechnology sector in the Unit for the Evaluation of Medicines for Human Use at the EMEA on 27 June 2000 and forwarded to the European Commission which adopted a decision on 11 August 2000. (EMEA/H/C/232/I/06)

<div style=\"page-break-after: always\"></div>

Subsequent  post  Marketing  Authorisation  applications  agreed  upon  are  summarised  in  the table below:

| Scope                                                                                                                                                        | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Change in the name and/or address of the marketing authorisation holder                                                                                      | I/07                 | I                        | 06.10.00                            | 27.12.00                                 |
| Change in pack size for a medicinal product                                                                                                                  | I/08                 | I                        | 12.12.00                            |                                          |
| Update of or change(s) to the pharmaceutical documentation                                                                                                   | II/09                | II                       | 23.08.01                            | 03.09.01                                 |
| Quality changes                                                                                                                                              | II/010               | II                       | 18.10.01                            | 31.10.01                                 |
| Addition of a manufacturing facility and two fold scale-up of purification process                                                                           | II/012               | II                       | 17.01.02                            | 23.01.02                                 |
| Additional drug product facility                                                                                                                             | II/013               | II                       | 17.01.02                            | 23.01.02                                 |
| Update of the SPC (point 4.8)                                                                                                                                | II/014               | II                       | 21.02.02                            | 25.06.02                                 |
| Compliance with Core SPC for human plasma                                                                                                                    | II/015               | II                       | 24.04.02                            | 20.08.02                                 |
| Change in supplier of an intermediate compound used in manufacture of the active substance                                                                   | I/016                | I                        | 29.10.01                            | 31.10.01                                 |
| Change in the name of manufacturer                                                                                                                           | I/020                | I                        | 29.01.02                            | 28.02.02                                 |
| New stopper for sodium chloride diluent                                                                                                                      | II/021               | II                       | 24.04.02                            | 29.04.02                                 |
| Line Extension                                                                                                                                               | X/022                | X                        | 19.09.02                            | 19.12.02                                 |
| Scale-up of MAb sepharose chromatography resin coupling process                                                                                              | II/023               | II                       | 21.11.02                            | 10.12.02                                 |
| Elimination of amino acid analysis testing on incoming KGSF 14 media                                                                                         | II/024               | II                       | 17.10.02                            | 21.10.02                                 |
| Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                             | N/025                | N                        | 23.08.02                            | 18.09.02                                 |
| Quality changes                                                                                                                                              | II/026               | II                       | 20.02.03                            | 08.05.03                                 |
| Change(s) to the test method(s) and/or specifications for the active substance                                                                               | II/027               | II                       | 20.03.03                            | 26.03.03                                 |
| Transfer of Marketing Authorisation Holder                                                                                                                   | T//028               | T                        | 31.03.03                            | 15.05.03                                 |
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process and Change in the name of a manufacturer of the active substance | I/029                | I                        | 18.07.03                            | 22.07.03                                 |
| Minor change of manufacturing process of the active substance                                                                                                | I/030                | I                        | 25.09.03                            | 02.10.03                                 |
| Extension of shelf-life or retest period of the active substance                                                                                             | I/035                | I                        | 22.09.03                            | 23.09.03                                 |

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.